Keyword: Regeneron Pharmaceuticals
Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?
Sanofi and Regeneron presented Odyssey outcomes data for Praluent at ACC 2018 Saturday.
Regeneron says a recent spike in a rare side effect for some Eylea patients is tied to some Becton Dickinson syringes that were distributed in the U.S.
Regeneron's Eylea has been a hit on the market for years. But now, the number of patients experiencing a rare side effect is climbing.
Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.
Monday, Axovant said COO Marion McCourt would be exit “to pursue another opportunity.” Turns out, that opportunity's at Regeneron.
Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.
Regeneron doesn't see a reason to worry about Eylea’s growth prospects. And after recent data presentations from rivals, some analysts agree.
The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.
With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.